Vectus Biosystems Ltd
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for cardiovascular fibrosis and systolic blood pressure, as well as treatments for cardiac fibrosis, kidney, liver, and lung fibrosis. Its lead compound is VB0004, currently under phase Ib clinical human trial, which is aimed at treating the loss of functional tissue t… Read more
Vectus Biosystems Ltd (VBS) - Total Liabilities
Latest total liabilities as of June 2025: AU$1.04 Million AUD
Based on the latest financial reports, Vectus Biosystems Ltd (VBS) has total liabilities worth AU$1.04 Million AUD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Vectus Biosystems Ltd - Total Liabilities Trend (2012–2025)
This chart illustrates how Vectus Biosystems Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Vectus Biosystems Ltd Competitors by Total Liabilities
The table below lists competitors of Vectus Biosystems Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AST Groupe
PA:ALAST
|
France | €106.64 Million |
|
DF Deutsche Forfait AG
XETRA:DFTK
|
Germany | €19.51 Million |
|
Megalestari Epack Sentosaraya Pt
JK:EPAC
|
Indonesia | Rp184.47 Billion |
|
NorCom Information Technology GmbH & Co. KGaA
XETRA:NC5A
|
Germany | €2.42 Million |
|
Focus Universal Inc
NASDAQ:FCUV
|
USA | $705.64K |
|
Traka Resources Ltd
AU:TKL
|
Australia | AU$184.14K |
|
MMEX Resources Corp
PINK:MMEX
|
USA | $6.99 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Vectus Biosystems Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -4.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vectus Biosystems Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vectus Biosystems Ltd (2012–2025)
The table below shows the annual total liabilities of Vectus Biosystems Ltd from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$1.04 Million | +92.72% |
| 2024-06-30 | AU$539.26K | -51.26% |
| 2023-06-30 | AU$1.11 Million | -86.76% |
| 2022-06-30 | AU$8.36 Million | -15.39% |
| 2021-06-30 | AU$9.88 Million | +1.75% |
| 2020-06-30 | AU$9.71 Million | +147.42% |
| 2019-06-30 | AU$3.92 Million | +59.99% |
| 2018-06-30 | AU$2.45 Million | +306.08% |
| 2017-06-30 | AU$603.99K | -35.45% |
| 2016-06-30 | AU$935.75K | +83.27% |
| 2015-06-30 | AU$510.57K | -22.93% |
| 2014-06-30 | AU$662.45K | +28.40% |
| 2013-06-30 | AU$515.93K | -56.18% |
| 2012-06-30 | AU$1.18 Million | -- |